Siga delivers first courses of smallpox antiviral drug Arestvyr to US
Arestvyr (Tecovirimat) is developed as a therapeutic against smallpox resulting from a terrorist attack, biowarfare or a new natural outbreak and is not yet cleared by the US
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.